AssetMark Inc
TSHA icon

AssetMark Inc’s Taysha Gene Therapies TSHA Stock Holding History

AssetMark Inc’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$36 Hold
8
– – ﹤0.01% 3409
2025
Q4 		$44 Buy
+8
New +$39 ﹤0.01% 3341

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AssetMark Inc's TSHA Position: Q1 2026 in Review

AssetMark Inc held its Taysha Gene Therapies (TSHA) position steady in Q1 2026 at 8 shares worth $36. The position accounts for ﹤0.01% of the portfolio, ranked #3409.

AssetMark Inc first reported a position in TSHA in Q4 2025 and has held it in 2 quarters since. The position peaked at $44 in Q4 2025. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • AssetMark Inc held 8 shares of Taysha Gene Therapies worth $36 as of Q1 2026.
  • AssetMark Inc left its Taysha Gene Therapies share count unchanged in Q1 2026.
  • Taysha Gene Therapies made up ﹤0.01% of AssetMark Inc's portfolio in Q1 2026, its #3409 holding.
  • AssetMark Inc first reported a position in Taysha Gene Therapies in Q4 2025 and has held it in 2 quarters since.
  • AssetMark Inc's Taysha Gene Therapies position peaked at $44 in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on AssetMark Inc's 13F filing for Q1 2026, filed 6 May 2026.